– ARCALYST® (rilonacept) Q3 2022 net revenue of $33.4 million –– RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
On 6ix: 6ix.com/news/kiniksa-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides
Watch Kiniksa Pharmaceuticals International's latest callKiniksa Pharmaceuticals International (NASDAQ:KNSA) Q3 2026 Earnings Call · Replay · Oct 27Read the transcript of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Q3 2026 Earnings CallKiniksa Pharmaceuticals International, plc on 6ix
In the deck
Story so far
- Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
- Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Earlier from Kiniksa Pharmaceuticals International
- Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
- Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
- Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
- Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
Later from Kiniksa Pharmaceuticals International
- Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
- Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
- Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
- Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
- Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
Follow Kiniksa Pharmaceuticals International into a list and get an email when it puts out news.
Follow Kiniksa Pharmaceuticals International